News & Views
Technology to Support Industrial Scale Cell Growth
Aug 11 2015
Lung stem cell technology developed at The University of Cambridge has been licenced to DefiniGEN Ltd, for development of optimised cell products and services for drug discovery, as well as the study of lung diseases, including cystic fibrosis.
The technology uses induced pluripotent stem cells, or iPS cells, to recreate embryonic lung development in the lab by activating a process known as gastrulation, in which the cells form distinct layers from which the lung ‘grows’. Uniquely, the technology also enables these cells to develop further into distal airway tissue. The distal airway is the part of the lung responsible for gas exchange and is often implicated in disease, such as cystic fibrosis, some forms of lung cancer and emphysema.
Commenting on the announcement, Dr Marcus Yeo, CEO of DefiniGEN, said: “This license enables us to use stem cells to grow highly functional lung cells on an industrial-scale for the first time. These cell products can then help researchers to elucidate key mechanisms of disease and enable pharmaceutical companies to screen for potential drugs in a reproducible and cost-effective way.”
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China